max estes

[John Woods @JohnAlanWoods]

Shout out to my compadre @marcvl. He is a brilliant creative mind and I love working with him.

He made @Android a household name and now he’s doing it again with @Algorand - give him a follow he’s building his X profile.

[$_Expert Para_$ @expert_para]

🔥 #AGX son 2 günde %15 arttı 🔥
önünde büyük bir potansiyel göze çarpıyor 👍

AGX destek seviyesinde kaldı ve tutundu 🔥

Neden daha fazla büyüme gelebilir 👇
✅️ Yaklaşık 6 milyon dolarlık düşük marketcap
✅️ $AGX olarak yeniden markalaşma ve güçlü ekip desteği
✅️ Yeni yapay zeka destekli ürün geliştirme aşamasında

Ekipten gelen açıklamada Yakında daha fazla haber bekleniyor 👍

$AGX yakın vadede hala potansiyel gösterebilir ve ve daha fazla büyüme beklenebilir 💥

Uniswap Link 👇 https://t.co/FT7QJnGnVX

👉 Önemli Not: İşbirliği Paylaşımıdır. Yatırım Tavsiyesi içermez 🚨

@0xAgix #altcoin #uniswap #cryptotrading

[sgsaltysoldier 🍌 @sgsaltysoldier]

Up the Torre dos Clérigos. Up on the charts. We are 🆙 only. 👆🏼🚀

[FrauHodl @FrauHodl]

Receptor-targeted lipid nanoparticles for mRNA delivery into T lymphocytes

- Prof. Dr. Christian Buchholz
– Paul-Ehrlich-Institut (PEI), Langen

ABSTRACT
RNA-delivering lipid nanoparticles (LNPs) have become key for vaccine development during the coronavirus pandemic.

Beyond vaccination, delivery of mRNA encoding therapeutic proteins by LNPs is establishing as alternative to viral vectors in gene therapy.

However, the clear majority of therapeutic strategies using RNA-LNPs focus on liver as target tissue, since the biomolecular corona formed on LNPs in vivo mediates a strong liver tropism.

Based on current understanding, this is due to apolipoprotein E (ApoE) which binds LNPs as well as low-density lipoprotein receptor (LDLR), which is highly expressed in liver.

This project aims at generating receptor-targeted RNA-LNPs that exhibit an extraordinarily high target cell selectivity while avoiding delivery to off-targets such as liver.

To achieve this, the applicant will transfer a strategy he successfully developed for viral gene transfer vectors to LNPs.

A high-affinity ligand for the target receptor of choice, in this case CD8, will be displayed on the LNP surface.

As CD8 binders, designed ankyrin repeat proteins (DARPins) directed against human or mouse CD8 will be incorporated into LNPs.

Binding of the particles as well as RNA delivery to CD8+ T cells will be monitored in comparison to conventional LNPs on T cell lines and primary donor lymphocytes isolated from blood. In vivo RNA delivery and biodistribution will be assessed in mouse models.

This work will result in basic insights into the biodistribution of RNA-LNPs as well as novel tools for mRNA delivery in cancer immunotherapy.

Beyond that, the strategy for receptor-targeting of LNPs can be easily adapted to any cell surface receptor of choice, thus further expanding potential applications of phospholipid research into various aspects of in vivo gene therapy.

[Prof B Buchanan OBE FRSE @billatnapier]

With the CSS08 method (based on the "Efficient Protocols for Set Membership and Range Proofs" paper), the verifier (Victor) sends a Boneh-Boyen Signature (BBS) of every element in a set. In this case, we will prove if x is in the range [a,b].

Read more: https://t.co/bHr06HjCvD

[SAMO @samoyedcoin]

Wanna keep up on the latest & greatest $SAMO whale purchases?

Join our Telegram, Famo! 👇
https://t.co/PYBdRrcGcd